Publications by authors named "M Tagliamento"
Introduction: The EORTC-Lung Cancer Group initiated a Delphi consensus process to establish a consensual definition of resectable stage III non-small cell lung cancer (NSCLC) for the use in clinical trials, including a systematic review, survey, and review of clinical cases. Here, the survey results are presented, aimed to identify areas of controversy.
Methods: A survey was distributed among the members of six international organizations related to lung cancer.
Assessing azithromycin's ecological toll: Unveiling multifaceted impacts on Poecilia reticulata THROUGH biomarker analysis.
Environ Toxicol Pharmacol
January 2025
This study investigates the impact of environmentally relevant concentrations of azithromycin on Poecilia reticulata, through biomarkers at different levels. To this end, the somatic indexes of P. reticulata were evaluated, and liver and gill samples were collected and analyzed for biochemical and histopathological alterations.
View Article and Find Full Text PDFBackground Tumor fraction (TF) at liquid biopsy is a potential noninvasive marker for tumor burden, but validation is needed. Purpose To evaluate TF as a potential surrogate for tumor burden, assessed at contrast-enhanced CT across diverse metastatic cancers. Methods This retrospective monocentric study included patients with cancer and metastatic disease, with TF results and contemporaneous contrast-enhanced CT performed between January 2021 and January 2023.
View Article and Find Full Text PDFAbout one third of patients with Non-Small Cell Lung Cancer (NSCLC) presents at diagnosis with localized or locally advanced disease amenable to curative surgical resection. Surgical operability refers to stage I to IIIA and selected stage IIIB NSCLC. One of the main challenges in the management of early-stage resectable NSCLC is the optimization of available therapeutic strategies to prevent local and distant disease relapse, thus improving survival outcomes.
View Article and Find Full Text PDFArticle Synopsis
- The study investigated the significance of metabolic tumor volume (tMTV) in patients with advanced non-small cell lung cancer (NSCLC) undergoing immune checkpoint blockade (ICB) therapy, using 18F-FDG-PET/CT scans.
- It involved 518 patients across multiple institutions and found that those with high tMTV had poorer overall survival when treated with ICBs alone compared to those with low tMTV.
- The research suggests that high tMTV is associated with increased systemic inflammation and genomic instability, making it a potential biomarker for determining treatment strategies in NSCLC patients with positive PD-L1 expression.